In cardiovascular, renal and metabolic disease, we are deepening our understanding not only of individual conditions, such as heart disease and diabetes, but also how they interact with and impact one another. Our aim is to move from slowing diseases and protecting organs to stopping diseases and regenerating organs.

In respiratory, we will continue improving our core offering of inhaled medicines to control symptoms, while pushing ahead with new biologics therapies for specific patient populations. With our early research, we aim for scientific breakthroughs to produce truly disease-modifying medicines which transform standards of care.

Our research efforts are focused on gaining a better understanding of the common biology and shared molecular pathways among inflammatory and autoimmune diseases, as well as the fundamental drivers and mechanisms of disease. Our aim is to identify and select drug targets with potential to effectively treat multiple diseases.

More than 90 percent of our pipeline now follows a precision medicine approach. We collaborate with a wide range of experts to identify, validate and develop diagnostics to regulatory standards globally, and to commercialise innovative biomarker capabilities for patient selection, disease identification, pharmacological assessment and drug response monitoring.

We are interested in cutting-edge technologies to enhance the quality, effectiveness and productivity of our research and translational capabilities.